pcn poster

Posters

AXS-05 (Dextromethorphan-Bupropion) Significantly Improved Functioning in Major Depressive Disorder: Analysis of the Domains of the Sheehan Disability Scale

Major Depressive Disorder carries a substantial economic burden and personal impairment to those it affects. In the GEMINI and COMET trials, AXS-05 demonstrated substantial improvements i...

Andrew J. Cutler , MD;

10/26/2023

Azithromycin in the Management of Clozapine-Induced Gastrointestinal Hypomotility

Clozapine induced gastrointestinal hypomotility (CIGH) is a common, often chronic, and potentially fatal complication of clozapine use. Although focus has historically been on constipatio...

Nikhil P. Rao , MD;

10/26/2023

Baseline Demographics and Clinical Characteristics From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia

OASIS was an observational study assessing real-world outcomes with atypical long-acting injectable (aLAI) antipsychotics in patients with schizophrenia. Most patients were treated in a c...

Lauren Strand , PhD, MS;

10/26/2023

Behavioral-, Neurologic-, Metabolic-, Endocrine-, and Cardiovascular-Related Adverse Events and Assessments in Patients With Schizophrenia Treated With TV-46000

TV-46000 is an FDA-approved long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone that was shown to reduce time to impending relapse in patients with schizophrenia. Th...

Kelli R. Franzenburg , PhD;

10/26/2023

Best Practices for Mental Health Treatment Teams From the Perspective of Certified Peer Support Specialists (CPSS): Results of a CPSS Roundtable

Certified Peer Support Specialists (CPSS) are people with lived experience who serve on treatment teams to help guide peers in their recovery process. A CPSS roundtable was convened to as...

LaGenia Bailey , PharmD, BCPP;

10/26/2023

Budget Impact of Aripiprazole Once Every Two Months Long-Acting Injectable for Adult Patients with Bipolar-I Disorder in the US

In this study, a cost-offset analysis was conducted to evaluate the budget impact of introducing a new 2-monthly injectable formulation of aripiprazole in commercial health plans. In a hy...

Vakaramoko Diaby ;

10/26/2023

Aripiprazole 2-Month Ready-to-Use: A Novel Long-Acting Injectable Antipsychotic Formulation for Administration Once Every 2 Months

Aripiprazole 2-month ready-to-use (Ari 2MRTU) is a novel long-acting injectable formulation of aripiprazole monohydrate for gluteal intramuscular administration. In the US, Ari 2MRTU is a...

Murat Yildirim , MD, PhD;

10/26/2023

Aripiprazole Lauroxil 2-Month Formulation for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Study

Positive and Negative Syndrome Scale (PANSS) factor scores (as described by Marder) were assessed in a post hoc analysis of data from adults with acute schizophrenia who received 25-week ...

Leslie Citrome , MD;

10/26/2023

Aripiprazole Once-Monthly for the Treatment of Adult Patients in the Earlier Stages of Bipolar I Disorder – a Post Hoc Analysis of Data From a Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Trial

This post hoc analysis of data from a double-blind, placebo-controlled, 52-week randomized-withdrawal trial (NCT01567527) was conducted to evaluate the efficacy of aripiprazole once-month...

Karimah S. Bell Lynum , PharmD, MBA, BCPP;

10/26/2023

Adjunctive Brexpiprazole in Patients With Major Depressive Disorder Including in a Subgroup With Energy/Concentration Symptoms: Time to Efficacy Onset

This post hoc pooled analysis of three randomized, fixed-dose, 6-week studies explored time to efficacy onset of adjunctive brexpiprazole 2–3 mg/day in patients with major depressive diso...

Shivani Kapadia ;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products